Ciprofloxacin ophthalmic solution USP, 0.3% as base, package in bottles: a) 10 mL (NDC 69315-308-10), b) 2.5 mL (NDC 69315-308-02), Rx Only, Distributed by: Leading Pharma LLC, Fairfield, NJ. Manufactured by: FDC Limited, Maharashtra, India.
Published August 7, 2024 · Recall initiated: July 23, 2024
Summary
FDA records drug Class II recall D-0623-2024, published August 7, 2024 and initiated July 23, 2024. Recalling firm: FDC Limited; Status: Ongoing; Reported quantity: 66,528 bottles; Lot: Lot#: a) 084C040, Exp 02/28/2026; b) 084A024, Exp12/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
What to do
Voluntary: Firm initiated · Letter
Get an email if CIPROFLOXACIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CIPROFLOXACIN
- Manufacturer
- FDC Limited
- Distributor
- U.S. A. Nationwide
- UPC
- 0369315308028
- Lot
- Lot#: a) 084C040, Exp 02/28/2026; b) 084A024, Exp12/31/2025.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- India
Related recalls
- FDACiprofloxacin Tablets, USP, 750 mg, 50-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. BoxNovember 11, 2026
- FDACiprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O.November 11, 2026
- FDACiprofloxacin Ophthalmic Solution USP, 0.3% as base, package in 5 mL bottles, Rx Only, Distributed by: LeadingMarch 26, 2025
- FDACiprofloxacin Ophthalmic Solution USP, 0.3% as base, Sterile, package in 5 mL bottles, Rx Only, DistributedJanuary 15, 2025
- FDAClonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg, 60 tablets per carton (10 blister cardsAugust 7, 2024
- FDAProgesterone Injection, USP, 500 mg per 10 mL (50mg/mL), 10 mL Multiple-Dose Vial, Rx Only, Mfd. in India for:August 7, 2024
Questions about this recall
Was Ciprofloxacin ophthalmic solution USP, 0.3% as base, package in bottles: a) 10 mL (NDC 69315-308-10), b) 2.5 mL (NDC 69315-308-02), Rx Only, Distributed by: Leading Pharma LLC, Fairfield, NJ. Manufactured by: FDC Limited, Maharashtra, India. recalled?
Yes. FDA published recall D-0623-2024 on August 7, 2024. Reported hazard: Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CIPROFLOXACIN. UPC: 0369315308028.